346672-52-4

Upstream product

• 252669-21-9 N-methoxy-N-methyl-2-(3-chlorophenyl)acetamide 
• 756-79-6 dimethyl methane phosphonate 
• 1878-65-5 3-chlorophenylacetic acid 
• 53088-68-9 methyl 3-chlorophenylacetate 

Downstream Products

• 1365178-52-4 ethyl (4R,5E)-8-(3-chlorophenyl)-4-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-7-oxo-5-octenoate 
• 884490-80-6 5-(3-{2-[4-(3-chloro-phenyl)-3-oxo-but-1-enyl]-5-oxo-pyrrolidin-1-yl}-propyl)-thiophene-2-carboxylic acid methyl ester 
• 533893-65-1 C₂₃H₃₀ClNO₄ 
• 494224-35-0 C₂₁H₂₈ClNO₄S 
• 494221-70-4 7-{(2R)-2-[(1E,3S)-3-hydroxy-4-(3-chlorophenyl)-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}heptanoic acid 
• 533893-55-9 ethyl 7-[(2R)-2-{(1E,3S)-3-hydroxy-4-(3-chlorophenyl)-1-buten-1-yl}-5-oxo-1-pyrrolidinyl]heptanoate 
• 635310-00-8 methyl 4-(2-{(5R)-2-oxo-5-[(1E)-3-oxo-4-(3-chlorophenyl)but-1-enyl]pyrrolidin-1-yl}ethyl)benzoate 

Relevant academic research and scientific papers

Discovery of orally available 8-aza-5-thiaProstaglandin E1 analogs as highly selective EP4 agonists

Analogs 8-aza-16-aryl prostaglandin E1 (PGE1) and 8-aza-5-thia-16-arylPGE1 were synthesized and evaluated with respect to their subtype receptor affinity and EP4 agonist activity for the purposes of identifying sub-type- selective EP

GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF

1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.

EP4 receptor selective agonists in the treatment of osteoporosis

This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R2, X, Z and Q are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds. This invention is also directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth in a mammal comprising administering those compounds.

EP4 receptor selective agonists in the treatment of osteoporosis

This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: wherein the variables are as defined in the specification.